J. Nakamura

P.2.c.001 Adding an atypical antipsychotic drug induced a rapid increase of plasma BDNF levels in refractory depression

P.2.f.011 Serum levels of BDNF, BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine (MRT) with major depressive disorder (MDD)

P.3.d.013 Effect of risperidone or blonanserin on cognitive function and psychotic symptoms in patients with acute phase schizophrenia

P.2.f.008 Duloxetine increased plasma levels of 3-methoxy-4-hydroxyphenylglycol in patients with major depressive disorder

P.6.e.002 Plasma levels of metabolites of catecholamine in nicotine dependent patients treated with varenicline

P.2.c.005 Plasma homovanillic acid levels and 5-HTTLPR gene polymorphism are predictive factors for sertraline in Japanese depressed patients

P.3.c.016 Cognitive functions and dosage of antipsychotic drugs in Japanese schizophrenia patients

P.2.a.009 Nonadherence to paroxetine; comparison between early-remitters and late-remitters

P.2.c.020 Effects of mirtazapine on brain-derived neurotrophic factor (BDNF) and catecholamine metabolites

P.2.a.003 Three polymorphisms of endothelial nitric oxide synthase (eNOS) gene and plasma NO3 levels